ROCHESTER, N.Y., Oct. 27 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. , a leading developer of image-based biomarker solutions, announced today that Dr. Edward Ashton, chief scientific officer, will present a joint seminar with Dr. Helen Young of AstraZeneca at the upcoming Center for Business Intelligence (CBI) 4th Annual Medical Imaging for Clinical Trials meeting, to be held October 26th and 27th in Tyson’s Corner, Virginia. The seminar, “Functional Imaging in Clinical Trials,” will provide a guide to the incorporation of dynamic and functional medical imaging into clinical trials of both pharmaceuticals and medical devices.
VirtualScopics’ seminar in functional imaging will present findings and lessons learned from several trials using dynamic contrast-enhanced magnetic resonance imaging (MRI) data to provide a method to directly measure blood flow and vessel permeability in tumors. This ability is vital for testing drugs designed to limit a tumor’s blood supply to starve and kill the tumor.
Founded in 1994 in Massachusetts, CBI Research, Inc. is dedicated to developing market-driven, unbiased conferences in pharmaceuticals\biotech, medical devices, risk and insurance and managed care markets. CBI Research, Inc. offers conferences and summits that serve senior executives and government officials by providing a unique platform for highly focused content and presentation. CBI’s annual Medical Imaging for Clinical Trials meeting presents two days of pharmaceutical/biotech case studies and in-depth sessions on how to leverage medical imaging as a clinical decision-making tool and how to apply imaging standards to support Food and Drug Administration (FDA) submissions.
“We are very pleased that we were not only asked to present our findings on functional imaging but that we are co-presenting with Dr. Young from one of our valued client companies, AstraZeneca,” said Jeff Markin president and CEO of VirtualScopics Inc. “Functional imaging can provide key information about drug safety and efficacy in the early and middle stages of clinical development.”
About VirtualScopics, Inc.
VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics’ industry- leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit www.virtualscopics.com.
Forward-Looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission.
CONTACT: Tracy Bagatelle-Black Bagatelle-Black Public Relations 661/263-1842 tracy@bagatelleblack.com Tim Ryan Trout Group Investor Relations 212 477 9007 x24 tryan@troutgroup.com
VirtualScopics, Inc.
CONTACT: Tracy Bagatelle-Black of Bagatelle-Black Public Relations,+1-661-263-1842, or tracy@bagatelleblack.com; or Tim Ryan of Trout GroupInvestor Relations, +1-212-477-9007 x24, or tryan@troutgroup.com
Web site: http://www.virtualscopics.com//
